HLA-C and neoplasm: In recent years, a milestone breakthrough in immunotherapy should be the chimeric antigen receptor T cell (CAR-T) therapy, which utilized T cells genetically modified to express CAR that redirect T-cell specificity towards tumor-associated antigens in an non major histocompatibility complex (MHC) restricted manner (1, 2).